GlassScriptPhysician profile
Sagar Sheth
NPI 1700469343
$1,659.86
in general payments reported to CMS, 2019-2025
18 companies · $1,149 in 2025
The $1,149 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $510 · 2025: $1,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,659.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $413.88 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Saluda Medical Americas, INC. | $194.46 | 2024 | Evoke |
| Amgen INC. | $178.81 | 2024-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $169.96 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $136.05 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $103.01 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.58 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $53.75 | 2025 | |
| Exact Sciences Corporation | $47.21 | 2024-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $45.31 | 2024-2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.17 | 2025 | Xifaxan |
| Abbvie INC. | $41.80 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $36.71 | 2025 | Breztri, Airsupra |
| Dexcom, INC. | $34.95 | 2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $34.10 | 2025 | Shingrix |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $29.57 | 2025 | Capvaxive |
| Boston Scientific Corporation | $17.60 | 2024 | Ranger |
| Currax Pharmaceuticals LLC | $15.94 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sagar Sheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.